Edwards Lifesciences (NYSE:EW) Sets New 12-Month High – Here’s Why

Edwards Lifesciences Corporation (NYSE:EW)’s share price reached a new 52-week high on Tuesday . The company traded as high as $89.60 and last traded at $88.7180, with a volume of 1681237 shares traded. The stock had previously closed at $86.28.

Wall Street Analyst Weigh In

EW has been the subject of several research analyst reports. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. TD Cowen reaffirmed a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Barclays reaffirmed an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Trading Down 2.3%

The company has a market capitalization of $49.83 billion, a PE ratio of 46.03, a price-to-earnings-growth ratio of 2.22 and a beta of 0.87. The company’s fifty day moving average is $83.14 and its 200-day moving average is $83.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the company. Washington Trust Advisors Inc. boosted its stake in Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after acquiring an additional 17,625 shares in the last quarter. Elo Mutual Pension Insurance Co boosted its stake in Edwards Lifesciences by 39.9% in the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after acquiring an additional 25,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after acquiring an additional 23,514 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after buying an additional 648,870 shares during the period. Finally, Central Pacific Bank Trust Division acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $775,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.